The agency said that although the Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.
A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.
The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...
NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.
Black TNBC Patients Lack Equitable Access to PARP Inhibitors, Flatiron Health Real-World Study Shows
Black patients were less likely to receive PARP inhibitors, despite having BRCA1/2 testing and positivity rates comparable to White patients, and were at higher risk of death.
The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback